Alexandre Joseph Buckmelter

This inventor holds 54 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Ubiquitin-Protease Inhibition (CPC class C07D). Top assignees: Forma Therapeutics, Inc., Array Biopharma Inc., Genentech, Inc.. Active years: 2008-2025.

USPTO Granted Patents = 54 (Patent Applications = 12)

% Patents Active = 88.9

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 7.3

ph-index = 12

Forward Citations = 435(Granted Patents)

Forward Citations (Not Self Cited) = 115(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boulder, CO (US) (2012 - 2013)
Superior, CO (US) (2008 - 2017)
Watertown, MA (US) (2015 - 2020)
Westford, MA (US) (2019 - 2021)
Acton, MA (US) (2017 - 2024)

Company Filing History:

22 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

7. 1 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

8. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

NAMPT Inhibition

Ubiquitin-Specific Protease

Pyrrolotriazinones

Quinazolinones

Purinones

Receptor Tyrosine Kinase

Bicyclic Compounds

Imidazotriazinones

Thienopyrimidinones

Peptidase Inhibitors

Pyrazolopyrimidines

Isothiazolopyrimidinones

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

2. 12049466 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors (2024-07-30),

3. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

4. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

5. 11795171 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2023-10-24),

6. 11739071 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2023-08-29),

7. 11547701 - Compounds and compositions for the inhibition of NAMPT (2023-01-10),

8. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) (2022-10-25),

9. 11279687 - Compounds and compositions for the inhibition of NAMPT (2022-03-22),

10. 11247987 - Inhibiting ubiquitin specific peptidase 30 (2022-02-15),

11. 11174273 - Quinazoline analogs as receptor tyrosine kinase inhibitors (2021-11-16),

12. 11161848 - Purinones as ubiquitin-specific protease 1 inhibitors (2021-11-02),

13. 10981915 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2021-04-20),

14. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2021-03-02),

15. 10927130 - Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-23),

Title: Inventor Alexandre Joseph Buckmelter

Introduction: Alexandre Joseph Buckmelter is a renowned inventor based in Acton, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Alexandre Joseph Buckmelter holds several patents in the areas of renewable energy technologies, medical devices, and consumer electronics.

Career Highlights: With a career spanning over two decades, Buckmelter has successfully developed and commercialized innovative solutions that have had a significant impact on society. His work has been recognized for its creativity and practicality.

Collaborations: Throughout his career, Alexandre Joseph Buckmelter has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Alexandre Joseph Buckmelter's passion for innovation and his dedication to improving the world through his inventions make him a standout figure in the field of inventors.